Our services

ADC Review
is made possible by:




ASCO 2017: Posters and Presentations – Online Only

The 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO) is expected offers a variety of engaging session formats—from debates, tumor boards, and abstract presentations to Meet the Professor sessions and case-based learning—providing attendees with expert insight and global perspectives on treatment and communication strategies.

Sessions integrate trending topics in oncology such as big data, clinical trial design, disparities, genomics, geriatric oncology, health policy, payment reform, rapid learning systems, and value. Detailed program information, including times, session titles, and faculty, is updated as it becomes available leading up to the Meeting

Below find an overview of Publication only abstracts related to Antibody-drug Conjugates


Time/Location  Title / Author(s)  Abstract/Session

Time:
This is a publication-only abstracts and not presented at the Meeting

Title:
Duration of second-line T-DM1 therapy: Is it associated with duration of first-line anti-Her2 therapy in metastatic HER2 + breast cancer?

Author(s):
Katz D, Feldhamer I,  Greenberg-Dotan S,  Hammerman A.

Abstract No:
e12512

Citation:
J Clin Oncol 35, 2017 (suppl; abstr e12512)

Time:
This is a publication-only abstracts and not presented at the Meeting

Title:
Effect of trastuzumab emtansine (T-DM1) on autologous platelet kinetics.

Author(s):
Gadi V, Corson J, Cundy A, Bailey S, Pellham E, Christoffel T, Gettinger I, Barroso J, Slichter S.

Abstract No:
e12521

Citation:
J Clin Oncol 35, 2017 (suppl; abstr e12521)

Time:
This is a publication-only abstracts and not presented at the Meeting

Title:
64Cu-DOTA-trastuzumab PET/CT to predict response to ado-trastuzumab emtansine (TDM1) in HER2-positive metastatic breast cancer.

Author(s):
Mortimer JE, Bading JR, Frankel PH, Gidwaney R, Park J, Tumyan L, Parayno M, et al

Abstract No:
e12525

Citation:
J Clin Oncol 35, 2017 (suppl; abstr e12525)

Time:
This is a publication-only abstracts and not presented at the Meeting.

Title:
Computational exploration of mechanistic determinants of antibody drug-conjugate pharmacokinetics using quantitative systems pharmacology modeling strategies.

Author(s):
Burke JM, Wilkins AK, Matteson A, Gruenbaum L, Apgar JF

Abstract No:
e14000

Citation:
J Clin Oncol 35, 2017 (suppl; abstr e14000)

Time:
This is a publication-only abstracts and not presented at the Meeting.

Title:
SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/neu expression.

Author(s):
Menderes G, Bonazzoli E, Beeline S, Black J, Altwerger G, Pettinella F, Masserdotti A, et al.

Abstract No:
e14009

Citation:
J Clin Oncol 35, 2017 (suppl; abstr e14009)

Time:
This is a publication-only abstracts and not presented at the Meeting.

Title:
ADR-201: A novel cytotoxic drug-conjugate for pancreatic cancer.

Author(s):
Ricigliano M, Cooper B, Bartlett A, Yu KH

Abstract No:
e14018

Citation:
J Clin Oncol 35, 2017 (suppl; abstr e14018)

Time:
This is a publication-only abstracts and not presented at the Meeting.

Title:
CD205, a target antigen for a novel antibody drug conjugate (ADC): Evaluation of antigen expression on non-Hodgkin lymphoma (NHL).

Author(s):
Canzonieri V, Gattei V, Spina M, Polizzi-Anselmo A, Attanasio N, Kaplan A, Bigioni M, et al.

Abstract No:
e14039

Citation:
J Clin Oncol 35, 2017 (suppl; abstr e14039)

Time:
This is a publication-only abstracts and not presented at the Meeting.

Title:
Antibody-nanoparticle conjugate constructed with trastuzumab and nab-paclitaxel for the targeted therapy of positive human epidermal growth factor receptor 2 gastric cancer.

Author(s):
Xiong J, Zhang H

Abstract No:
e15506

Citation:
J Clin Oncol 35, 2017 (suppl; abstr e15506)

Time:
This is a publication-only abstracts and not presented at the Meeting.

Title:
Targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 expressing bladder cancer using combination photoimmunotherapy (PIT).

Author(s):
Siddiqui MR, Railkar RS, Sanford T, Choyke PL, Kobayashi H, Agarwal PK

Abstract No:
e16026

Citation:
J Clin Oncol 35, 2017 (suppl; abstr e16026)

Time:
This is a publication-only abstracts and not presented at the Meeting.

Title:
Harnessing IMGN853-mediated cell cytoxicity response by modulating FRα expression in ovarian cancer.

Author(s):
Kumar R, Wei W,  Lauffer S, Fulci G, Birrer MJ

Abstract No:
e17061

Citation:
J Clin Oncol 35, 2017 (suppl; abstr e17061)

Time:
This is a publication-only abstracts and not presented at the Meeting.

Title:
A trial-based EuroQol EQ-5D health utility analysis in patients with classical Hodgkin lymphoma.

Author(s):
Wu E, Liao J, Balakumaran A

Abstract No:
e19011

Citation:
J Clin Oncol 35, 2017 (suppl; abstr e19011)

Time:
This is a publication-only abstracts and not presented at the Meeting.

Title:
Ranolazine and TDM1 treatment: Cardioprotective effects in vitro and in vivo.

Author(s):
Maurea N, Coppola C, Piscopo G, Riccio G, Rea D, De Vecchis R, Maurea C, et al.

Abstract No:
e23102

Citation:
J Clin Oncol 35, 2017 (suppl; abstr e23102)


Last editorial review: May 29, 2017

Copyright © 2017 InPress Media Group, LLC. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Share

Manuscript Guidelines & Tips

Skip to toolbar